Genes such as BUD23, MARS1, METTL6, METTL2B, LCMT1, AHCY, SEPHS1, and SEPHS2 were consistently upregulated in multiple cancer types, suggesting a broad role in tumor progression, whereas MAT2B, AHCYL1, AHCYL2, GGT7, and PAPSS2 were frequently downregulated, with GGT6 showing pronounced suppression in renal cancers. This evidence concerns the gene METTL2B and renal carcinoma.